Tenofovir-induced leukocytoclastic vasculitis

Said A. Al-Busafi*, Abdulatif Al-Suleimani, Aysha Al-Hamadani, Wasif Rasool

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Tenofovir, a nucleotide analog, is one of the first-line medications recommended for the treatment of active chronic hepatitis B virus infection (CHB) and as a primary prophylaxis to prevent hepatitis B reactivation in cases of immunosuppression. We report the first case of tenofovir-induced leukocytoclastic vasculitis (LCV). A 43-year-old obese woman, who was known to have inactive CHB, was diagnosed with chronic immune thrombocytopenic purpura (ITP). She was treated with corticosteroid therapy and was put on tenofovir to prevent hepatitis B virus reactivation. A month later, she developed a skin rash, described as non-blanchable well-defined erythematous to violaceous papules and targetoid patches in her lower extremities. A skin biopsy showed features of LCV. The rash resolved completely within few days after replacing tenofovir with entecavir.

Original languageEnglish
Pages (from-to)429-431
Number of pages3
JournalOman Medical Journal
Issue number5
Publication statusPublished - Sept 2017


  • Hepatitis B
  • Leukocytoclastic vasculitis
  • Tenofovir

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Tenofovir-induced leukocytoclastic vasculitis'. Together they form a unique fingerprint.

Cite this